Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-labeled Cimzia scintigraphy in inflammatory arthritis and Crohn's disease
2009-017998-37Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of certolizumab pegol in rheumatoid arthritis (RA), spondyloarthritis (SpA), Crohn's disease and 1 more (4 arms), sponsored by Ghent University Hospital. Primary endpoint: Clinical remission discontinuation rule. Started Apr 2012; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)spondyloarthritis (SpA)Crohn's diseaseerosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on 2009-017998-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017998-37.